Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: 25th European Workshop for Rheumatology Research

Poster presentation

Expression of programmed death (PD)-1 and PD-1 ligands (PD-L1, PD-L2) in peripheral blood mononuclear cells of patients with systemic lupus erythematosus

G Bertsias, A Raptopoulou, E Coutala, M Mamoulaki, H Kritikos, P Sidiropoulos and DT Boumpas

Author affiliations

Department of Rheumatology, Clinical Immunology and Allergy, Medical School, University of Crete, Greece

For all author emails, please log on.

Citation and License

Arthritis Research & Therapy 2005, 7(Suppl 1):P153  doi:10.1186/ar1674

The electronic version of this article is the complete one and can be found online at:


Received:11 January 2005
Published:17 February 2005

© 2005 BioMed Central Ltd

Background

Programmed death (PD)-1 is a newly described member of the immunoglobulin super-family that is expressed on activated T lymphocytes and B lymphocytes. Engagement of PD-1 with its specific ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), inhibits lymphocyte proliferation and cytokine expression, and may play a role in peripheral tolerance and negative regulation of T-cell and B-cell responses in vivo. We sought to investigate the expression profiles of PD-1 and PD-1 ligands in peripheral blood cells of patients with systemic lupus erythematosus (SLE).

Materials and methods

Blood was drawn from patients with SLE (n = 16), rheumatoid arthritis (n = 16), other inflammatory disease (n = 4), and healthy controls (n = 9). Peripheral blood mononuclear cells were separated on a ficoll-density gradient, and flow cytometry analysis was performed using monoclonal antibodies against CD3, CD19, CD14, CD25, CD69, PD-1, PD-L1, and PD-L2.

Results

See Table 1.

Conclusions

In this preliminary report, SLE patients showed a trend for lower expression of PD-1 and higher expression of PD-L1 in unstimulated peripheral blood mononuclear cells compared with other disease controls. These results corroborate findings linking SLE with polymorphism of the PD-1 gene resulting in putative altered expression of the PD-L2 [1]. Lower expression of PD-1 in SLE lymphocytes could be related to ineffective suppression of autoreactive lymphocytes and thus to disease evolution. Currently, we investigate expression of PD-1 and its ligands on subpopulations of lymphocytes (CD45RO+, CD27+), as well as the kinetics of expression upon stimulation.

References

  1. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al.: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.

    Nat Genet 2002, 32:666-669. PubMed Abstract | Publisher Full Text OpenURL